Asalyxa is focused on the rapid development of a revolutionary neutrophil-targeting drug platform. The versatility of Asalyxa’s proprietary platform allows for the direct delivery of microparticles into neutrophils, making the platform ideal for a variety of diseases where treatments are limited or do not exist. Asalyxa is committed to developing neutrophil targeting treatments for diseases with a high unmet medical need, allowing today’s patients to enjoy a healthier tomorrow.